Biotechnology company Athernal Bio has announced its official launch, aiming to develop targeted immunotherapies for high-risk clonal haematopoiesis (CH).  The launch follows funding worth £3.5 million ($4.7 million) from venture capital firm Delin Ventures. It is hoped that the financial backing can support preclinical milestones as Athernal Bio intends to move towards clinical trials in […]